Right‐sided non‐recurrent laryngeal nerve without any vascular anomaly: an anatomical trap

We really appreciate Craig et al. (2016) for their commended to our contribution to the current knowledge about Zika Virus (ZIKV), and their comments to the possible relationship between Guillain-Barre syndrome (GBS) and ZIKV infection (Saiz et al., 2016). Even more, we absolutely agree with their interpretations and recommendations pointing to the necessity of further research to accurately quantify the effect of enhanced surveillance related to ZIKV circulation and associated risks. In fact, we clearly stated in the abstract of our review (Saiz et al., 2016) and throughout the text, including our final remarks, that clarifying whether there is a causal link between ZIKV infection and GBS is a currently unavoidable goal. In this regard, recently, we have specifically addressed what it is currently known about ZIKV infections in relation with neurological manifestations (Blazquez and Saiz, in press), and stated that, beside the reported data pointing to a relationship between ZIKV infection and GBS, so far, a causal association has not been yet solidly established. GBS is a clinical syndrome of multiple autoimmune etiologies and the most common and severe acute paralytic neuropathy (van den Berg et al., 2014; Willison et al., 2016). In in many cases GBS appears to be associated with antecedent infectious diseases (Winner, 2001), and sporadic arboviral infections with dengue virus, DENV (Garg et al., 2015; Simon et al., 2016), West Nile virus, WNV (Sejvar, 2004), or chikungunya virus, CHIKV (Wielanek et al., 2007) have already been associated to GBS. In fact, Malone et al. (2016) have suggested that the concomitant regional increase in DENV and CHIKV infections may have contribute to the recently registered increase in GBS incidence. In any case, and beyond the considerable efforts carried out by the scientific community and the national and international health authorities focused on deciphering ZIKV infection and its consequences, sufficient resources should be allocated to provide the necessary tools to evaluate the potential mechanisms of ZIKV association to GBS.

[1]  M. Scully,et al.  Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. , 2017, Blood advances.

[2]  D. Brody,et al.  Clinical and imaging assessment of acute combat mild traumatic brain injury in Afghanistan , 2015, Neurology.

[3]  P. Eggleton Hypersensitivity: Immune Complex Mediated (Type III) , 2013 .

[4]  G. Ling,et al.  Neurology and the military: Five new things. , 2013, Neurology. Clinical practice.

[5]  A. Payne,et al.  Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. , 2012, The Journal of allergy and clinical immunology.

[6]  H. Gopal,et al.  Serum sickness and severe angioedema following rituximab therapy in RA , 2012, International journal of rheumatic diseases.

[7]  M. Raichle,et al.  Detection of blast-related traumatic brain injury in U.S. military personnel. , 2011, The New England journal of medicine.

[8]  J. Monroe,et al.  B‐cell targeted therapies in human autoimmune diseases: an updated perspective , 2010, Immunological reviews.

[9]  H. Goto,et al.  Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura , 2009, International journal of hematology.

[10]  S. Helfgott,et al.  Serum sickness following treatment with rituximab. , 2007, The Journal of rheumatology.

[11]  J. Cavenagh,et al.  Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13 , 2007, British journal of haematology.

[12]  X. Mariette,et al.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.

[13]  K. Saito,et al.  Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. , 2005, Rheumatology.

[14]  Robert Jackson Serum Sickness , 2000, Journal of cutaneous medicine and surgery.

[15]  Sharon Willis,et al.  Uniformed Services University of the Health Sciences. , 2003, Academic medicine : journal of the Association of American Medical Colleges.